Adeno-associated virus-mediated survivin mutant Thr34Ala cooperates with oxaliplatin to inhibit tumor growth and angiogenesis in colon cancer

作者：Xue, Zhimou; Sun, Ping Hu; Zhu, Li Ming; Jiang, Shi Hu; Qiao, Min Min; Chi, Alfred L.; Tu, Shu Ping^*

来源：Oncology Reports, 2011, 25(4): 1039-1046.

DOI：10.3892/or.2011.1166

• survivin mutant T34A
• adeno-associated virus
• colon cancer
• apoptosis
• mitotic catastrophe
• angiogenesis

Colon cancer is one of the most common cancers. Survivin is overexpressed in human colon cancer and correlate with chemoresistance, angiogenesis and poor prognosis. Oxaliplatin, a platinum derivative cancer drug, has been used for treating human colorectal cancers. In the present study, we investigated the effect of the adeno-associated virus (AAV)-mediated survivin mutant Thr34Ala [rAAV-Sur-Mut(T34A)] on colon cancer growth. Infection with rAAV-Sur-Mut(T34A) inhibited cell proliferation, induced apoptosis and mitotic catastrophe, and sensitized colon cancer cells to chemotherapeutic drugs in vitro. Treatment with rAAV-Sur-Mut(T34A) significantly induced apoptosis, reduced angiogenesis and inhibited colon cancer growth in vivo. More importantly, rAAV-Sur-Mut(T34A) treatment strongly enhanced the antitumor activity of oxaliplatin and prolonged animal survival. Thus, the use of rAAV-Sur-Mut(T34A) in combination with chemotherapy may be a promising strategy for colon cancer therapy.

• 出版日期2011-4
• 单位上海交通大学; 苏州大学; 上海市闵行区中心医院